The S-100B level, intracranial pressure, body temperature, and transcranial blood flow velocities predict the outcome of the treatment of severe brain injury

Sebastian Dzierzęcki, MD, PhD\textsuperscript{a,b,}\textasteriskcentered, Miroslaw Ząbek, MD, PhD\textsuperscript{a,c}, Gabriela Zapolska, MD, PhD\textsuperscript{d}, Ryszard Tomasik, MD, PhD\textsuperscript{e}

Abstract

This study evaluates the applicability of S100B levels, mean maximum velocity ($V_{\text{mean}}$) over time, pulsatility index (PI), intracranial pressure (ICP), and body temperature ($T$) for the prediction of the treatment of patients with traumatic brain injury (TBI). Sixty patients defined by the Glasgow Coma Scale score $\leq$ 8 were stratified using the Glasgow Coma Scale into 2 groups: favorable (FG: Glasgow Outcome Scale $\geq$ 4) and unfavorable (UG: Glasgow Outcome Scale $< 4$). The S100B concentration was at the time of hospital admission. $V_{\text{mean}}$ was measured using transcranial Doppler. PI was derived from a transcranial Doppler examination. $T$ was measured in the temporal artery. The differences in mean between FG and UG were tested using a bootstrap test of 10,000 repetitions with replacement. Changes in S100B, $V_{\text{mean}}$, PI, ICP, and $T$ levels stratified by the group were calculated using the one-way aligned rank transform for nonparametric factorial analysis of variance. The reference ranges for the levels of S100B, $V_{\text{mean}}$ and PI were 0.05 to 0.23 µg/L, 30.8 to 73.17 cm/s, and 0.62 to 1.13, respectively. Both groups were defined by an increase in $V_{\text{mean}}$; a decrease in S100B, PI, and ICP levels; and a virtually constant $T$. The unfavorable outcome is defined by significantly higher levels of all parameters, except $T$. A favorable outcome is defined by S100B $< 3$ mg/L, PI $< 2.86$, ICP $> 25$ mm Hg, and $V_{\text{mean}} > 40$ cm/s. The relationships provided may serve as indicators of the results of the TBI treatment.

Abbreviations: CBF = cerebral blood flow, CBI = craniocerebral injury, CPP = cerebral perfusion pressure, CT = computerized tomography, FG = favorable group, GOS = Glasgow Outcome Scale, GCS = Glasgow Coma Scale, ICP = intracranial pressure, MRI = magnetic resonance imaging, PI = pulsatility index, $T$ = body temperature, TBI = traumatic brain injury, TCD = transcranial Doppler, UG = unfavorable group, $V_{\text{mean}}$ = mean maximum velocity.

Keywords: biomarkers, brain injury, diagnosis, Doppler, neurosurgery, transcranial

1. Introduction

Traumatic brain injury (TBI) is the result of brain damage caused by angular and/or linear acceleration or deceleration forces leading to axonal injury. It manifests itself as neurological, neuropsychological, and psychiatric dysfunction.\textsuperscript{1}$

In developed countries, the incidence of TBI is 0.2% of the population per year among hospitalized patients.\textsuperscript{2} Every year, almost 2 million people suffer from minor TBI worldwide, leading to temporary disability.\textsuperscript{3} However, in the United States and Europe, almost 20 and 15 people per 100,000, respectively, die from TBI.\textsuperscript{2}

The age distribution for TBI is as follows: 15 to 30, 30 to 60, and \textgreater60 years.\textsuperscript{3} TBI is most often seen between 15 and 30 years of age, while it is less common in the age group of 30 to 60 years. In the broad spectrum of TBI, it is possible to distinguish craniocerebral injury (CBI), a condition that is often interchangeably used with brain injury.\textsuperscript{4}

CBI most frequently affects 2 age groups: 15 to 24 and \textgreater75 years.\textsuperscript{5} Although it is internationally prevalent at 1.3 and 2.0 cases per 100,000 in North America and Europe, it oscillates around 0.07 cases per 100,000 in Poland. However, the high frequency of CBI imposes severe economic stress on health and insurance services due to costly and complicated treatment and rehabilitation processes.\textsuperscript{6–8}

The research reported in this publication was supported by the Commission for Scientific Research of the Medical Center for Postgraduate Education in Warsaw Research Grant No.: 501-2-1-20-49/04. The authors have no conflicts of interest to disclose.

The datasets generated during and/or analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request. Data reported in this study are available on request to Sebastian Dzierzecki at smd@neurochirurg.pl.

*Correspondence: Sebastian Dzierzecki, Warsaw Gamma Knife Centre, Brodno Masovian Hospital, Kondratowicza 8 Building H, 03-242 Warsaw, Poland (e-mail: smd@neurochirurg.pl).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Dzierzecki S, Ząbek M, Zapolska G, Tomasiuk R. The S-100B level, intracranial pressure, body temperature, and transcranial blood flow velocities predict the outcome of the treatment of severe brain injury. Medicine 2022;101:38(jl230348).

Received: 4 September 2021 / Received in final form: 6 February 2022 / Accepted: 27 June 2022

http://dx.doi.org/10.1097/MD.0000000000030348
There are a variety of methods that facilitate the diagnosis of TBI and CBI. They include the Glasgow Coma Scale (GCS), computerized tomography (CT), magnetic resonance imaging (MRI), transcranial Doppler (TCD), and measurements of cerebral perfusion pressure (CPP) and biochemical blood markers.

Therefore, the severity of CBI can be assessed using GCS for patients whose total score indicates a high level of consciousness. CT and MRI are frequently used in the diagnosis of TBI. CT helps to accurately detect life-threatening and surgically treatable intracranial hemorrhages in patients with TBI and CBI. However, it provides a moderately valid prognosis. MRI is the overall superior method for the detection and prognosis of TBI. However, it has a limited ability to detect axonal injury. TCD is a noninvasive technique that allows real-time monitoring of CPP, intracranial pressure (ICP), and cerebral blood flow (CBF). TCD spectral analysis is also used to determine the maximum systolic velocity, the end-diastolic velocity, and the mean maximum velocity (Vmax) in onsonated blood vessels. The clinical practicality of Vmax measurement has been confirmed in severe cases of TBI. CPP was used to assess the pulsatility index (PI) values of the middle cerebral artery. CBF levels were evaluated using mean blood flow velocity.

To date, a variety of blood biomarkers have been proposed for the diagnosis of acute TBI. They include lactate dehydrogenase, myelin alkaline protein, neuron-specific enolase, creatine kinase, and S100B. S100B has been shown to play a crucial role in intracellular processes and induce apoptosis at micromolar concentrations.

Body temperature (T) measurement was also considered a diagnostic factor for patients with TBI. Although brain temperature cannot be reliably predicted from T, some recommend monitoring brain and body temperatures to reduce the risk of temperature-related neuronal damage.

Since the effectiveness of CBI treatment is a derivative of diagnostic quality, there is an ongoing exploration of parameters applicable to a robust, rapid, and error-free prediction of the severity and diagnosis of CBI. Therefore, this study was designed to address the need to build a reliable diagnostic tool for the diagnosis of CBI. The study evaluated the usability of a battery of diagnostic markers, including S100B, Vmax, PI, ICP, and T. It was carried out in patients stratified into 2 groups, that is, favorable (FG) and unfavorable (UG) outcomes, defined by the GCS score evaluated 30 days after hospital admission.

2. Methods

2.1. Study subjects

This study was carried out according to the regulations of the Bioethics Committee of the Warsaw Medical Center for Postgraduate Education and Trauma of the Nervous System of the Medical Center of Postgraduate Education, Warsaw, Poland. Informed consent was obtained from all subjects or their guardians and, if subjects were under 18 years old, from their parents and/or legal guardians prior to the study.

After admission to the Department of Neurosurgery and Trauma of the Nervous System, the health of the patients was evaluated using the GSC. All of them were subjected to standard diagnostic and therapeutic procedures. However, those with poor ventilation underwent a gasometric examination to optimize pCO2 range: 30–40 mm Hg) and maintain hematocrit and hemoglobin levels at 30% to 40% and 12 to 14 g/dL, respectively.

Only those with a GCS score ≤ 8 were included in the study. Therefore, the study group comprised 60 patients (48 men and 12 women) age range 21 to 75 years; the GCS and the corresponding Marshall scale of the patients included in the study are shown in Figure 1. Study samples comprising FG and UG were obtained by stratification using the Gosling outcome scale (GOS) and evaluated on the day of hospital discharge. The UG consisted of patients with a GOS score < 4, and the FG consisted of patients with a GOS score ≥ 4.

2.2. Parameters and laboratory methods

The parameters studied in this study were measured at 24-hour intervals for 96 hours, 30 days after admission to the Department of Neurosurgery.

S100B concentration was measured in 5 mL of venous blood samples collected from patients at hospital admission. Subsequent blood samples were collected at 24-hour intervals for 96 hours. After clotting and centrifugation for 10 minutes at 1000 revolutions per minute, blood samples were stored for further use at −22°C. S100B concentration was measured using a commercially available kit (Liaison Sangtec 100). The Sangtec 100 kit uses 3 different monoclonal antibodies (SMST12, SMSK25, and SMSK28) directed against the β-chains of the S100B homodimer and defines a broad diagnostic spectrum between 0.02 and 30.00 µg/L. Protein concentration was measured using a (LIAISON analyzer, Saluggia, Italy) calibrated with a freeze-dried (Sangtec 100 Cal, Dietzenbach, Germany) (low/high) calibrator. The sensitivity threshold for this test was 0.02 µg/L.

Vmax was measured by subjecting patients to TCD using a Medisonic Transpect CDS Doppler in power motion mode (PMD/TCD). It was a 2-step procedure: First, the accessible arteries of the brain base were examined through the temporal window, and second, the middle cerebral arteries on the dominant or right side of the extent of the lesion were further analyzed.

PI was derived from a TCD examination performed using a Medisonic Transpect CDS Doppler in PMD/TCD. Initially, the brain base arteries accessible through the temporal window were scanned. However, further analysis conducted on the middle cerebral arteries on the dominant or right side of the lesion’s extent was symmetrical.

For each patient, ICP and CPP were measured using implanted microsensor ICP (Codman) sensors. After reset, the ICP sensors were placed in the last stage of surgical removal of the intracranial hematoma or within hours of admission for patients without the characteristics of the intracranial hematoma. All surgical patients underwent osseous dural decompression, which consisted of removing the bone flap and opening the dura mater as wide as possible.

![Figure 1](image-url) - Clinical classification of patients admitted to the Department of Neurosurgery and Trauma of the Nervous System of the Medical Center of Warsaw, Poland. (A) GCS score distribution; (B) MCTC score distribution. Numerals correspond to the number of cases (percentage of cases). GCS = Glasgow Coma Scale, MCTC = Marshall Computed Tomography Classification, TBI = traumatic brain injury.
T was measured by temporal artery temperature. This method is based on infrared emissions radiating from the skin. To minimize measurement-induced errors, each measurement was repeated 3 times and an average of 5 temperature readings was reported. T measurements that differed more than 0.5°C were rejected from the mean calculation of T.

The self-assessed S100B, V mean, and PI reference ranges were determined using a group of 40 healthy volunteers, 25 men and 15 women, with an average age of 47.0 ± 14.77 (range: 21–80) years.

2.3. Statistical analysis

The normality test was performed using the Shapiro–Wilk test. Data are expressed as mean ± standard deviation and median with minimum and maximum values. Computation of the rate of change in a parameter was performed using a linear regression model. Differences in the means of the study groups, that is, FG and UG at specific time points, were tested using a bootstrap test for differences in the means of 10,000 repetitions with replacement. Changes in S100B, V mean, PI, ICP, and T levels stratified by the study group were calculated using the one-way linear rank transform for the nonparametric factorial analysis of variance technique. Because of the shortcomings of current statistical methods in handling advanced nonparametric statistics, only the result of one-way nonparametric factorial analysis of variance has been discussed in this study. Patient mortality was taken into account by censoring the number of subjects in a group. The rate of change of a specific parameter was evaluated using the slope of a linear regression model. V values < 0.01 were considered statistically significant. All analyses were performed using the R programming language.

3. Results

The stratification scheme led to the post hoc assignment of 36 and 24 patients to UG and FG, respectively. The average age of the patients in the UG was 49 years (range 20–72) and that of the FG was 48 years (range 24–75). The standard reference range was 0.05 to 0.23 μg/L, 30.8 to 73.17 cm/s, and 0.62 to 1.13 for the S100B, V mean and PI levels, respectively. Changes in S100B, V mean, PI, ICP, and T levels of the S100B group (measured at 30, +2, +3, and +4 days after hospital admission) are presented in Tables 1A and 1B. Differences between UG and FG at a specific time point for the levels of S100B, V mean, PI, ICP, and T are provided in Table 2. A graphical representation of the changes in S100B, V mean, PI, ICP, and T levels stratified by outcome groups is shown in Figures 2A and B–6A and B.

Analysis of normality unfolded different, in terms of normality, distributions of studied samples. This observation led to employment of bootstrap test for differences in the means. Such an approach allowed to overcome challenges of nonparametric statistics. Moreover, due to nonparametric nature of sample distribution, nonparametric factorial analysis of variance had to be employed to elucidate meaningful statistics.

No statistically significant time-dependent differences in S100B concentration were found in UG. However, a significant decrease in serum S100B levels was determined between 30 and +3 days in the FG measurements. The respective data are compiled in Tables 1A and 1B and Figure 2. The S100B levels of the UG patients were significantly higher than those of the FG at all measurement time points. The respective data are provided in Table 2. The difference in the S100B decrease velocity between the UG and the FG showed a relative decrease of 0.19, with velocities V S100B=0.007g/L/h and V S100B=0.037g/L/h for the UG and FG, respectively.

An analysis of the data provided in Tables 1A and 1B and Figure 3 shows that the V mean levels of the patients in the UG are characterized by a statistically lower V mean than those of the FG 30 and 31 days after hospital admission. Statistically significant differences in V mean levels were observed between 30 and +3 days in FG. There were no statistically significant differences in mean V mean levels in the UG. The relative difference in V mean levels between the UG and the FG was 1.4 V mean UG=0.21 cm/s/h and V mean FG=0.15 cm/s/h.

Changes in PI levels are presented in Tables 1A and 1B and Figure 4. PI levels of UG patients were significantly higher than those of FG (Table 2). FG was defined by a decrease in PI (V PI=0.14/day) and the lack of statistically significant differences between consecutive measurements. UG was defined by the lack of significant differences between the measurements, and the rate of decrease in PI was V PI=0.22/day. The relative ratio of the rate of decrease in PI between the UG and FG was V PI UG/V PI FG=−0.006 0.009=0.65.

| Parameter | Time (d) | Mean | SD | Median | Min | Max |
|-----------|---------|------|----|--------|-----|-----|
| S-100B    | 30      | 6.45 | 4.77 | 4.71   | 1.67| 19.41|
|           | 31      | 5.23 | 3.43 | 4.42   | 1.14| 16.67|
|           | 32      | 4.47 | 3.83 | 3.45   | 0.93| 20.38|
|           | 33      | 3.74 | 3.15 | 3.25   | 0.79| 15.91|
|           | 31      | 27.15| 8.18 | 25.44  | 5.18| 42.03|
|           | 31      | 34.00| 13.96| 31.7   | 6.04| 60.02|
|           | 32      | 34.64| 26.18| 33.75  | 5.06| 118.46|
|           | 33      | 39.97| 31.57| 36.83  | 6.22| 142.46|
| V mean    | 30      | 3.46 | 2.92 | 2.86   | 1.11| 6.61 |
|           | 31      | 1.03 | 1.23 | 1.03   | 1.05| 6.76 |
|           | 32      | 1.23 | 1.30 | 1.23   | 1.05| 6.76 |
| ICP       | 30      | 46.23| 13.44| 46.12  | 27.01| 86.71|
|           | 31      | 33.64| 13.58| 35.61  | 11.12| 66.52|
|           | 32      | 34.59| 15.32| 28.94  | 9.18 | 80.05|
|           | 33      | 34.45| 15.34| 37.2   | 7.21 | 60.74|
| T         | 30      | 37.54| 0.92 | 37.45  | 36.13| 39.73|
|           | 31      | 37.54| 0.90 | 37.42  | 35.89| 39.64|
|           | 32      | 37.53| 1.43 | 37.29  | 35.52| 40.85|
|           | 33      | 37.97| 0.85 | 37.92  | 36.36| 39.35|

ICP = intracranial pressure, PI = pulsatility index, SD = standard deviation, T = body temperature, UG = unfavorable group, V mean = mean maximum velocity.
Changes in ICP levels are provided in Tables 1A and 1B and Figure 5. Differences in mean ICP levels between FG and UG are summarized in Table 2. ICP levels in the FG were significantly higher at all measurement time points than those in the UG (Table 2). UG was defined by a decrease rate of $V_{ICP_{UG}} = 0.14$ mm Hg/h, and FG was defined by a decrease rate of $V_{ICP_{FG}} = 0.16$ mm Hg/h. The relative ratio of changes in ICP levels between UG and FG was $0.88$ mm Hg/h.

Table 1B: Descriptive statistics of S-100b, $V_{mean}$, PI, ICP, and $T$ levels as a function of hospitalization time in the FG.

| Parameter | Time (d) | Mean | SD  | Median | Min | Max |
|-----------|----------|------|-----|--------|-----|-----|
| S-100b    | 30       | 1.40 | 0.48| 1.37   | 0.74| 2.73|
|           | 31       | 1.14 | 0.45| 1.00   | 0.48| 1.9 |
|           | 32       | 1.19 | 0.48| 1.24   | 0.39| 2.07|
|           | 33       | 0.83 | 0.36| 0.85   | 0.14| 1.61|
| $V_{mean}$| 30       | 43.92| 8.58| 42.76  | 31.68|65.52|
|           | 31       | 51.95| 13.72|47.71 | 36.13|83.67|
|           | 32       | 50.12| 11.79|49.74 | 29.02|73.04|
|           | 33       | 61.27| 10.73|61.24 | 39.49|87.87|
| PI        | 30       | 2.04 | 0.39| 2.06   | 1.23| 2.87|
|           | 31       | 1.66 | 0.41| 1.57   | 1.09| 2.92|
|           | 32       | 1.61 | 0.47| 1.57   | 0.95| 2.97|
|           | 33       | 1.31 | 0.44| 1.30   | 0.64| 2.51|
| ICP       | 30       | 26.15| 6.27| 27.15  | 13.59|38.44|
|           | 31       | 19.42| 4.49| 18.54  | 11.27|27.88|
|           | 32       | 17.95| 5.75| 17.35  | 10.26|33.95|
|           | 33       | 14   | 4.58| 13.19  | 7.09| 23.51|
| $T$       | 30       | 36.95| 0.18| 36.94  | 36.67|37.34|
|           | 31       | 37.12| 0.45| 37.16  | 36.45|37.92|
|           | 32       | 37.38| 0.45| 37.3   | 36.79|38.15|
|           | 33       | 37.32| 0.36| 37.22  | 36.91|37.95|

FG = favorable group, ICP = intracranial pressure, PI = pulsatility index, SD = standard deviation, $T$ = body temperature, $V_{mean}$ = mean maximum velocity.

Table 2: Statistical differences between means of analogous measurements for FG and UG.

| Parameter | Time (d) | FG mean | UG mean | $P < .01$ |
|-----------|----------|---------|---------|-----------|
| S-100b    | 30       | 1.40    | 6.45    | *         |
|           | 31       | 1.14    | 5.23    | *         |
|           | 32       | 1.19    | 4.47    | *         |
|           | 33       | 0.84    | 3.74    | *         |
| $V_{mean}$| 30       | 43.92   | 27.15   | *         |
|           | 31       | 51.95   | 34.00   | *         |
|           | 32       | 50.12   | 34.64   | *         |
|           | 33       | 61.45   | 38.97   | *         |
| PI        | 30       | 2.04    | 3.46    | *         |
|           | 31       | 1.66    | 2.92    | *         |
|           | 32       | 1.61    | 2.98    | *         |
|           | 33       | 1.31    | 2.95    | *         |
| ICP       | 30       | 26.15   | 46.23   | *         |
|           | 31       | 19.42   | 33.64   | *         |
|           | 32       | 17.95   | 34.59   | *         |
|           | 33       | 14.11   | 34.45   | *         |
| $T$       | 30       | 36.95   | 37.54   | *         |
|           | 31       | 37.12   | 37.54   | *         |
|           | 32       | 37.38   | 37.53   | *         |
|           | 33       | 37.34   | 37.97   | *         |

FG = favorable group, ICP = intracranial pressure, PI = pulsatility index, $T$ = body temperature, UG = unfavorable group, $V_{mean}$ = mean maximum velocity.

* $P < .01$.

4. Discussion

Among the techniques used to predict the results of TBI and CBI treatment are mathematical models such as the International Mission for Prognosis and Clinical Trials in Traumatic Brain Injury and Corticosteroid Randomization after Significant Head Injury. However, they are of poor precision at the individual patient level.

In the search for prognostic methods for TBI, studies of biological markers were carried out. However, most of the studies conducted so far lack good discriminatory capacity. A new biomarker has recently been proposed for the diagnosis and prediction of the outcome of the treatment of TBI and CBI: the S100B protein. Furthermore, analysis of CBF velocity, particularly $V_{mean}$ and PI, is derived through the TCD examination and can also be used in the diagnosis and prediction of...
the outcome of the treatment of TBI and CBI. A recent study has also shown that monitoring ICP levels influences treatment methods and can reduce mortality in people with severe TBI.

This study attempted to advance knowledge of the applicability of specific markers and design a new diagnostic method and prediction of the outcome of TBI treatment. Therefore, a simultaneous analysis of changes in S100B, \( V_{\text{mean}} \), PI, ICP, and \( T \) levels was performed in patients with CBI stratified by treatment outcomes. To our knowledge, this is the first attempt to combine these parameters for the diagnosis and prediction of results.
Additionally, the standard reference range for S100B, $V_{\text{mean}}$, and PI levels was obtained during this study. The reference range for the standard S100B concentration established in this study was 0.02 to 0.23 µg/L. This result differs from the previously proposed concentration, 0.02 to 0.15 µg/L. The mean of the reference range was 0.1 µg/L, which differs from the previously reported value for Caucasians (0.07 µg/L) and indicates S100B levels in the range of the Asian population. Furthermore, it is similar to the mean value reported for Asians (0.11 µg/L). Since S100B levels appear to depend on age, the observed difference may be the product of different male-to-female ratios and different mean ages of the study sample. This study shows that both treatment outcome groups (i.e., FG and UG) are defined by S100B levels significantly greater than the normal range. However, the levels observed in the UG are 4.5 times higher than those in the FG. Furthermore, assuming a continuous decrease in S100B levels at the rates observed for UG and FG ($V_{\text{S100B,UG}} = 0.007 \text{g/L/h}$ and $V_{\text{S100B,FG}} = -0.037 \text{µg/L/h}$), the additional time required to reach the standard range would be 50.0 and 16.5 hours for UG and FG, respectively. This observation indicates that recovery of normal levels of S100B is crucial for the results of CBI and TBI treatment.

In this study, the reference range for the $V_{\text{mean}}$ was 30.8 to 73.17 cm/s, while previous studies reported a range of 30 to 60 cm/s. Although the lower limits are similar, the upper limits reported in this study are higher. In the current state, it is difficult to identify what is causing this difference. Among the possible factors may be the age of the study sample, the male-to-female ratio, differences in mean arterial pressure, and differences in $pCO_2$. Analysis of changes in $V_{\text{mean}}$ as a function of treatment results helped determine levels in the third quartile of the normal reference range in the FG and in the first quartile of the normal reference range in the UG. Furthermore, the rate of increase in the $V_{\text{mean}}$ levels that define the UG was 1.4 times greater than that observed in the FG: $V_{\text{mean,UG}} = 0.21 \text{cm/s/h}$ and $V_{\text{mean,FG}} = 0.15 \text{cm/s/h}$. The results presented by van Santbrink et al., in conjunction with the results of this study, confirmed that an unsatisfactory outcome of TBI treatment is defined by reducing the velocity of CBF. This study also confirmed previous data on the relationship between mean blood flow velocity and the outcome of TBI treatment (44 and 36 cm/s for good and poor outcomes, respectively), showing that FG was defined by overall $V_{\text{mean}}$ levels greater than those observed in UG (54.5 and 33.69 cm/s for FG and UG, respectively).

In this study, the reference range for PI levels was 0.62 to 1.13. The previously reported reference range was 0.5 to 1.19. According to a previous study, a PI level < 0.5 may indicate arteriovenous malformation or proximal stenosis occlusion, while a PI level > 1.199 may indicate constriction or distal occlusion. PI ≤ 1.0 defines patients with GOS scores of 4 to 5, while patients with a PI level ≥ 1.56 are at risk of poor treatment results. However, others reported a PI level of 1.25 as the threshold that defines the results of TBI treatment. This study confirmed the ranges but not absolute values of the previous study (good result = 1.00 and poor result = 1.56) through the relations of the overall PI means 1.52 and 2.95 for FG and UG, respectively. Therefore, in this study, the result that defines the poor outcome in the previous study refers to a favorable outcome. Since both studies used an analogous GOS stratification model, that is, scores 1 to 3 (1 = death, 2 = vegetative state, and 3 = severe disability) were considered “poor” and unfavorable outcomes, and scores 4 to 5 (4 = moderate disability and 5 = complete recovery or correct outcome) were considered “good” and favorable outcomes; the etiology of the observed differences is unknown.

Elevation of ICP levels is accompanied by an incidence of brain injury that may be caused, among others, by reduced cerebral blood flow and delayed energy supply. Currently, there is a lack of cross-correlation studies between $T$ and the prognosis of treatment for CBI. Although a healthy brain is resistant to fever compared to the injured brain, prolonged exposure to fever can result in infarcted brain cells. Therefore, elevated brain temperature has been shown to result in an increased risk of unfavorable outcomes in CBI treatment. Since core $T$ and an increase in cerebral metabolism of 1°C increase cerebral metabolism by 7% to 13%, both groups are defined by a small increase
in cerebral metabolism of the order of 3 to 6 and 2.5% to 5.0% for UG and FG, respectively. Furthermore, the previous study showed the lack of direct correlation between body and brain temperatures in disease. However, our study revealed significantly higher $T$ in the UG than in the FG, indicating $T$ as the prediction parameter of the outcome of treatment. Currently, the etiology of this phenomenon is unknown. It may be caused by the release of factors that increase $T$, such as cytokines, interleukins, and white blood cells. However, taking into account the observation that brain temperature in head trauma patients is on average 0.22°C higher than $T_{90}$, and that normal $T$ is at 37.5°C, UG patients are defined by the detrimental increase in $T$ that was reflected in treatment outcomes.

The analysis of time-dependent changes revealed the following relations between the parameters studied in FG and UG, respectively: (1) an apparent increase in $V_{\text{mean}}$ levels; a decrease in levels of S100B, PI, and ICP levels; and a virtually constant $T$ (Fig. 7A); (2) an increase in $V_{\text{mean}}$ levels; a decrease in levels of ICP, S100B, and PI levels; and constant $T$ (Fig. 7B). Although both groups are defined by the analogous direction of changes in the parameters studied, it is clear that UG is defined by higher levels of ICP, $T$, S100B, and PI and lower levels of $V_{\text{mean}}$.

In conclusion, it can be stated that S100B < 3 mg/L, PI < 2.86, ICP > 25 mm Hg, and $V_{\text{mean}} > 40$ cm/s define the group of favorable outcomes. Although more studies are required to design a robust outcome prediction model, the data provided may already serve as an indicator of the results of TBI treatment.

This presented study in a novel combination, not published elsewhere, of multiparameter analysis allowing to observe cross-correlation among the studied parameters; S100B, PI, ICP, and $V_{\text{mean}}$, allowing for more accurate proetidion of treatment outcome in clinical environment.

Nevertheless, to improve the statistical power of the studied correlations, we envisage to extend the number of subjects studied as well as introduce a multicenter study.

### References

1. Romodanov AP, Pedachenko EG. [Features of the clinical manifestation of contusion of the cerebral hemisphere in patients with hypertension]. Zh Vopr Neirokhir Im N N Burdenko. 1983;3:3–6.
2. Bruns J Jr, Hauser WA. The epidemiology of traumatic brain injury: a review. Epilepsia. 2003;44:2–10.
3. Dawodu ST. Traumatic brain injury (TBI) – definition, epidemiology, pathophysiology. Med Reference: Drugs, Diseases and Procedures. 2011. Available at: http://emedicine.medscape.com/article/326510-overview.
4. Selzet E. Cranioencephalic injuries. Calif Med. 1956;84:292–4.
5. Toccalino D, Colantonio A, Chan V. Update on the epidemiology of work-related traumatic brain injury: a systematic review and meta-analysis. Occup Environ Med. 2021;78:769–76.
6. Pape HC, Neugebauer E, Ridley SA, et al. Cost-drivers in acute treatment of severe trauma in Europe: a systematic review of literature. Eur J Trauma Emerg Surg. 2009;35:61–6.
7. Chappuis G, Soltermann B, Cea, Aredoc, Ceredoc. Number and cost of claims linked to minor cervical trauma in Europe: results from the comparative review study by CEA, AREDOC and CEREDOC. Eur Spine J. 2008;17:1350–7.
8. Berg J, Tagliaferri F, Servadei F. Cost of trauma in Europe. Eur J Neuroul. 2005;12(Suppl 1):85–90.
9. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet (London, England). 1974;2:81–4.
10. Brody DL, Mac Donald CL, Shimony JS. Current and future diagnostic tools for traumatic brain injury: CT, conventional MRI, and diffusion tensor imaging. Handb Clin Neurol. 2015;127:267–75.
11. Blennow K, Brody DL, Kochanek PM, et al. Traumatic brain injury. Nat Rev Dis Primers. 2016;2:16084.
12. Yeh EL, Mukherjee P, Lingsma HH, et al. Magnetic resonance imaging improves 3-month outcome prediction in mild traumatic brain injury. Ann Neurol. 2013;73:224–35.
13. Purkayastha S, Sorond F. Transcranial Doppler ultrasound: technique and application. Semin Neuroul. 2012;32:411–20.
14. Smith M. Cerebral perfusion pressure. BJA: Br J Anaesth. 2008;100:6–11.
15. Yuh EL, Mukherjee P, Lingsma HF, et al. Magnetic resonance imaging improves 3-month outcome prediction in mild traumatic brain injury. Ann Neurol. 2013;73:224–35.
16. Cardim D, Robba C, Bohdanowicz M, et al. Non-invasive monitoring of intracranial pressure using transcranial Doppler ultrasonography: is it possible? Neurocrit Care. 2016;25:473–91.
17. Tegeler C, Ratanakorn D. Physics and principles. In: Babikian V, Wechsler L, eds. Transcranial Doppler Ultrasonography. Waltham, MA: Butterworth-Heinemann; 1999:3–11.
18. Ract C, Le Moigno S, Bruder N, et al. Transcranial Doppler ultrasound goal-directed therapy for the early management of severe traumatic brain injury. Intensive Care Med. 2007;33:645–51.
19. Calviello LA, de Riva N, Donnelly J, et al. Relationship between brain pulsatility and cerebral perfusion pressure: replicated validation using different drivers of CPP change. Neurocrit Care. 2017;27:392–400.
20. Fatima N, Shauki A, Chughtai TS, et al. The role of transcranial doppler in traumatic brain injury: a systemic review and meta-analysis. Asian J Neurosurg. 2019;14:626–33.
21. Rao CJ, Shukla PK, Mohanty S, et al. Predictive value of serum lactate dehydrogenase in head injury. J Neurosurg Psychiatry. 1978;41:948–53.
Dzierzak M, Wobbrock J. ARTool: Aligned Rank Transform for
Flynn MR. Analysis of censored exposure data by constrained maximiza-
Duncan A, Bell A, Chu K, et al. Can a non-contact infrared thermome-
Jennett B, Bond M. Assessment of outcome after severe brain damage:
Marshall LF, Marshall SB, Klauber MR, et al. The diagnosis of head
Soukup J, Zauner A, Doppenberg EM, et al. The importance of brain
Ross SA, Cunningham RT, Johnston CF, et al. Neuron-specific eno-
Statistical Science. Berlin, Heidelberg: Springer Berlin Heidelberg;
Jiang JY, Gao GY, Li WP, et al. Early indicators of prognosis in 846 cases
Myburgh JA, Cooper DJ, Finfer SR, et al. Epidemiology and 12-month outcomes from traumatic brain injury in Australia and New Zealand. J Trauma. 2008;64:854–62.
Thornhill S, Teasdale GM, Murray GD, et al. Disability in young people and adults one year after head injury: prospective cohort study. BMJ. 2000;320:1631–5.
Nydakis MS, Ling GS, Mulligan LP, et al. Epidemiologic aspects of traumatic brain injury in acute combat casualties at a major military medical center: a cohort study. Ann Neurolog. 2012;72:673–81.
Kraus JF, Mc Arthur DL. Epidemiologic aspects of brain injury. Neurol Clin. 1996;14:435–50.
Theilin EP, Nelson DW, Bellander B-M. A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury. Acta Neurochir. 2017;159:209–25.
Dadas A, Washington J, Diaz-Arrastia R, et al. Biomarkers in traumatic brain injury (TBI): a review. Neuropsychiatr Dis Treat. 2018;14:2989–3000.
Yuan Q, Wu X, Cheng H, et al. Is intracranial pressure monitoring of patients with diffuse traumatic brain injury valuable? An observational multicenter study. Neurosurgery. 2015;76:361–9.
Madden LD, DeVon HA. A systematic review of the effects of body temperature on outcome after adult traumatic brain injury. J Neurosci Nurs. 2015;47:190–203.
Piazza O, Russo E, Cotena S, et al. Elevated S100B levels do not correlate with the severity of encephalopathy during sepsis. Br J Anaesth. 2007;98:518–21.
Ben Abdesselam O, Vally J, Adem C, et al. Reference values for serum S-100B protein depend on the race of individuals. Clin Chem. 2003;49:836–7.
Portela IV, Tort AB, Schaaf DV, et al. The serum S100B concentration is age dependent. Clin Chem. 2002;48(6 Pt 1):950–2.
Figure 2: The serum S100B concentration is age dependent.
Clinical significance of the S100B protein. J Neurotrauma. 2002;19:559–71.
Maas AI, Steyerberg EW. Monitoring prognosis in severe traumatic brain injury. Crit Care. 2014;18:150.
Lingsma H, Andriessen TM, Haissema I, et al. Prognosis in moderate and severe traumatic brain injury: external validation of the IMPACT models and the role of extracranial injuries. J Trauma Acute Care Surg. 2013;74:639–46.
Rouzos P, Lingsma HH, Lecky FE, et al. Prediction of outcome after moderate and severe traumatic brain injury: external validation of the International Mission on Prognosis and Analysis of Clinical Trials (IMPACT) and Corticoid Randomisation After Significant Head injury (CRASH) prognostic models. Crit Care Med. 2012;40:1609–17.
Jiang JY, Gao GY, Li WP, et al. Early indicators of prognosis in 846 cases of severe traumatic brain injury. J Neurotrauma. 2002;19:869–74.
Myburgh JA, Cooper DJ, Finfer SR, et al. Epidemiology and 12-month outcomes from traumatic brain injury in Australia and New Zealand. J Trauma. 2008;64:854–62.
Thorhill S, Teasdale GM, Murray GD, et al. Disability in young people and adults one year after head injury: prospective cohort study. BMJ. 2000;320:1631–5.
Nydakis MS, Ling GS, Mulligan LP, et al. Epidemiologic aspects of traumatic brain injury in acute combat casualties at a major military medical center: a cohort study. Ann Neurolog. 2012;72:673–81.
Kraus JF, McArthur DL. Epidemiologic aspects of brain injury. Neurol Clin. 1996;14:435–50.
Theilin EP, Nelson DW, Bellander B-M. A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury. Acta Neurochir. 2017;159:209–25.
Dadas A, Washington J, Diaz-Arrastia R, et al. Biomarkers in traumatic brain injury (TBI): a review. Neuropsychiatr Dis Treat. 2018;14:2989–3000.
Yuan Q, Wu X, Cheng H, et al. Is intracranial pressure monitoring of patients with diffuse traumatic brain injury valuable? An observational multicenter study. Neurosurgery. 2015;76:361–9.
Madden LD, DeVon HA. A systematic review of the effects of body temperature on outcome after adult traumatic brain injury. J Neurosci Nurs. 2015;47:190–203.
Piazza O, Russo E, Cotena S, et al. Elevated S100B levels do not correlate with the severity of encephalopathy during sepsis. Br J Anaesth. 2007;98:518–21.
Ben Abdesselam O, Vally J, Adem C, et al. Reference values for serum S-100B protein depend on the race of individuals. Clin Chem. 2003;49:836–7.
Portela IV, Tort AB, Schaaf DV, et al. The serum S100B concentration is age dependent. Clin Chem. 2002;48(6 Pt 1):950–2.
Wiesmann M, Missler U, Gottmann D, et al. Plasma S-100B protein concentration in healthy adults is age- and sex-independent. Clin Chem. 1998;44:1056–8.
White H, Venkatesh B. Applications of transcranial Doppler in the ICU: a review. Intensive Care Med. 2006;32:981–94.
Schatlo B, Pluta RM. Clinical applications of transcranial Doppler ultrasonography. Rev Recent Clin Trials. 2007;2:49–57.
van den Berg CD, Vlot J, Steggerda SJ, et al. Transcranial Doppler measurements in traumatic brain injury with special focus on the early posttraumatic period. Acta Neurochir. 2002;144:1141–9.
Moreno JA, Mesalles E, Gener J, et al. Evaluating the outcome of severe head injury with transcranial Doppler ultrasonography. Neurosurg Focus. 2007;20(4):E7.
Nicoletti HA, Burkan MH. Transcranial Doppler series part IV: case studies. Am J Electroencephalogr Technol. 2009;49:342–60.
Nicoletti HA, Burkan MH. Transcranial Doppler series part III: interpretation. Am J Electroencephalogr Technol. 2009;49:244–59.
Bouzat P, Franchy C, Delecy P, et al. Transcranial Doppler to screen on admission patients with mild to moderate traumatic brain injury. Neurosurg. 2011;68:1603–9; discussion 1609.
Mollan SP, Spitzer D, Nicholl DJ. Raised intracranial pressure in those with head injury or skeletal muscle damage? FASEB J. 2017;31:lb123–lb123.
Piazza O, Russo E, Cotena S, et al. Elevated S100B levels do not correlate with the severity of encephalopathy during sepsis. Br J Anaesth. 2007;98:518–21.
Ben Abdesselam O, Vally J, Adem C, et al. Reference values for serum S-100B protein depend on the race of individuals. Clin Chem. 2003;49:836–7.
Portela IV, Tort AB, Schaaf DV, et al. The serum S100B concentration is age dependent. Clin Chem. 2002;48(6 Pt 1):950–2.
Wiesmann M, Missler U, Gottmann D, et al. Plasma S-100B protein concentration in healthy adults is age- and sex-independent. Clin Chem. 1998;44:1056–8.
White H, Venkatesh B. Applications of transcranial Doppler in the ICU: a review. Intensive Care Med. 2006;32:981–94.
Schatlo B, Pluta RM. Clinical applications of transcranial Doppler ultrasonography. Rev Recent Clin Trials. 2007;2:49–57.
van den Berg CD, Vlot J, Steggerda SJ, et al. Transcranial Doppler measurements in traumatic brain injury with special focus on the early posttraumatic period. Acta Neurochir. 2002;144:1141–9.
Moreno JA, Mesalles E, Gener J, et al. Evaluating the outcome of severe head injury with transcranial Doppler ultrasonography. Neurosurg Focus. 2007;20(4):E7.
Nicoletti HA, Burkan MH. Transcranial Doppler series part IV: case studies. Am J Electroencephalogr Technol. 2009;49:342–60.
Nicoletti HA, Burkan MH. Transcranial Doppler series part III: interpretation. Am J Electroencephalogr Technol. 2009;49:244–59.
Bouzat P, Franchy C, Delecy P, et al. Transcranial Doppler to screen on admission patients with mild to moderate traumatic brain injury. Neurosurg. 2011;68:1603–9; discussion 1609.
Mollan SP, Spitzer D, Nicholl DJ. Raised intracranial pressure in those presenting with headache. BMJ. 2018;363:k3252.
Gnoosen MC, Huijben JA, van der Jagt M, et al. Variation in monitoring and treatment policies for intracranial hypertension in traumatic
brain injury: a survey in 66 neurotrauma centers participating in the CENTER-TBI study. Crit Care. 2017;21:233–233.
[77] Carney N, Totten AM, O’Reilly C, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery. 2017;80:6–15.
[78] Chesnut R, Videtta W, Vespa P, et al. The participants in the international multidisciplinary consensus conference on multimodality M. Intracranial pressure monitoring: fundamental considerations and rationale for monitoring. Neurocrit Care. 2014;21:64–84.
[79] Bellner J, Romner B, Reistrup P, et al. Transcranial Doppler sonography pulsatility index (PI) reflects intracranial pressure (ICP). Surg Neurol. 2004;62:45–51; discussion 51.
[80] Cabella B, Donnelly J, Cardim D, et al. An association between ICP-derived data and outcome in TBI patients: the role of sample size. Neurocrit Care. 2017;27:103–7.
[81] Balesteri M, Czosnyka M, Hutchinson P, et al. Impact of intracranial pressure and cerebral perfusion pressure on severe disability and mortality after head injury. Neurocrit Care. 2006;4:4–13.
[82] Sheth KN, Stein DM, Aarabi B, et al. Intracranial pressure dose and outcome in traumatic brain injury. Neurocrit Care. 2013;18:26–32.
[83] Karaszewski B, Carpenter TK, Thomas RGR, et al. Relationships between brain and body temperature, clinical and imaging outcomes after ischemic stroke. J Cereb Blood Flow Metab. 2013;33:1083–9.
[84] Childs C, Vail A, Leach P, et al. Brain temperature and outcome after severe traumatic brain injury. Neurocrit Care. 2006;5:10–4.
[85] Sacho RH, Vail A, Rainey T, et al. The effect of spontaneous alterations in brain temperature on outcome: a prospective observational cohort study in patients with severe traumatic brain injury. J Neurotrauma. 2010;27:2157–64.
[86] Kluger MJ, Kozak W, Leon LR, et al. Cytokines and fever. Neuroimmunomodulation. 1995;2:216–23.
[87] Herrmann O, Tarabin V, Suzuki S, et al. Regulation of body temperature and neuroprotection by endogenous interleukin-6 in cerebral ischemia. J Cereb Blood Flow Metab. 2003;23:406–15.
[88] Waalen J, Buxbaum J. Is older colder or colder older? The association of age with body temperature in 18,630 individuals. J Gerontol A Biol Sci Med Sci. 2011;66:487–92.
[89] Wang H, Olivero W, Lanzino G, et al. Rapid and selective cerebral hypothermia achieved using a cooling helmet. J Neurosurg. 2004;100:272–7.
[90] Wang H, Wang B, Normoyle KP, et al. Brain temperature and its fundamental properties: a review for clinical neuroscientists. Front Neurosci. 2014;8:1–17.
[91] Geneva II, Cuzzo B, Fazili T, et al. Normal body temperature: a systematic review. Open Forum Infect Dis. 2019;6:ofz032–ofz032.